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Abstract 33 
Medication adherence in drug trials is suboptimal, affecting the quality of these studies and 34 
adding significant costs.  Non-adherence in this setting can lead to null findings, unduly large 35 
sample sizes, and the need for dose modification after a drug has been approved. Despite 36 
these drawbacks, adherence behaviours are not consistently measured, analysed or reported 37 
appropriately in trial settings. The ESPACOMP Medication Adherence Reporting Guideline 38 
(EMERGE) offers a solution, by facilitating a sound protocol design that takes this crucial factor 39 
into account. This article summarises key evidence on traditional and newer measurements 40 
of adherence, discusses implementation in clinical trial settings, and makes recommendations 41 
about the analysis and interpretation of adherence data. Given the potential benefits of this 42 
approach, the authors call on regulators and the pharmaceutical industry to endorse the 43 
EMERGE guideline. 44 
 45 
Key words 46 
Adherence; Clinical trials, Pharmacokinetic-Pharmacodynamic 47 
[Heading 1] Introduction 48 
Adherence to treatment should be reported in all clinical trials. This call has been repeated 49 
for more than 20 years [1-4] but unfortunately, proper consideration of adherence remains 50 
the exception rather than the rule. Too often, adherence is neglected at every stage of the 51 
research process, from trial design and conduct through to data analysis and reporting in the 52 
literature. The consequences are concerning. If adherence is prevalent and unrecognised in a 53 
trial, it can potentially confound safety and efficacy signals, and obscure exposure-response 54 
estimations [1-4]. If we do not know whether patients followed their treatment accurately 55 
during a trial – and why they did so, or why they did not – our understanding of how the drug 56 
will work in clinical practice may be dangerously flawed. 57 
 58 
Until recently, the lack of concise guidance on how adherence should be measured, analysed 59 
and reported in clinical trials has been a barrier. Now, the International Society for Medication 60 
Adherence (ESPACOMP) Medication Adherence Reporting Guideline (EMERGE) offers a 61 
solution [5].   62 
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This is a tool that can readily be applied alongside recommendations from the US Food and 63 
Drug Administration (FDA) [6] and the European Medicines Agency (EMA) [7]. EMERGE has 64 
also been designed to complement the Consolidated Standards of Reporting Trials (CONSORT, 65 
for randomised controlled trials) [8] and the Strengthening the Reporting of Observational 66 
Studies in Epidemiology (STROBE) standards [9].   67 
 68 
In addition to complementing existing clinical trial guidelines, EMERGE aims to increase 69 
transparency and consistent reporting on adherence by offering a list of 21 items that include 70 
minimum reporting criteria, and more detailed recommendations for each element of a 71 
research report (the abstract; introduction; methods including study design and participants, 72 
measurement, intervention and statistical analysis;  results; and discussion) [5].  73 
 74 
The EMERGE development methodology has been previously reported [5]. In brief, the 75 
guideline was developed through a Delphi process involving an international panel of experts. 76 
The group followed the recommended procedure outlined by the Enhancing the QUAlity and 77 
Transparency Of health Research (EQUATOR) group [10]. Like other reporting guidelines, 78 
while EMERGE offers a list of essential criteria, it does not extend to  providing methodological 79 
recommendations. 80 
 81 
This paper thus has a dual aim. It provides a comprehensive summary of recommendations 82 
for measurement, analysis and interventions related to treatment adherence in drug trial 83 
settings. When used in combination with EMERGE, this paper can guide trial sponsors and 84 
researchers as they develop drug trial protocols aligned with other key guidelines, which 85 
specify that participants’ adherence to investigational products and trial protocols should be 86 
adequately reported [8,11]. It is also a call to pharmaceutical regulators to take decisive action 87 
to officially endorse EMERGE and to give appropriate consideration of adherence and its 88 
impact on drug development [5]. Clear guidance from regulatory approval organisations is 89 
key to driving change in the pharmaceutical industry.  90 
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 91 
[Heading 1] Background 92 
 93 
Non-adherence to appropriately prescribed treatments is a substantial and costly problem 94 
that can severely impact both trials and practice, through reduced clinical benefit and 95 
increased risk of morbidity and mortality [12, 13]. In clinical practice, up to 50% of patients 96 
do not take their medications as prescribed [14] and estimates point to non-adherence 97 
accounting for up to 48% of asthma deaths, an 80% increased risk of death in diabetes and a 98 
3.8-fold increased risk of death in the year following a heart attack [15]. The related cost to 99 
health care systems across the world is substantial: the cost of unused medicines has been 100 
estimated to reach £300 million per year in the United Kingdom [16]. 101 
Adherence in clinical trial settings is also suboptimal. Blaschke et al. (2012) compiled 102 
adherence data captured by electronic measurements from 16,907 participants across 95 103 
clinical trials. They found an initial drop of 4% due to non-initiation. By day 100, 20% of 104 
participants were non-persistent (i.e. had stopped taking treatment against protocol 105 
specifications) and, among persistent patients, daily,  a further 15% displayed sub-optimal 106 
implementation [17].  107 
However, assessment and reporting of adherence and drug discontinuation in clinical trials is 108 
lacking.  One recent systematic review of medication adherence in RCTs evaluating 109 
cardiovascular or mortality outcomes in dialysis patients found that, of 22 clinical trials that 110 
met the inclusion criteria, only five reported measuring individual-level medication adherence 111 
[18]. All five of these trials also presented results demonstrating negative study outcomes for 112 
the medication under investigation.     113 
A striking example of the impact of adherence on efficacy comes from a set of randomised 114 
controlled trials (RCTs) assessing pre-exposure prophylaxis (PrEP) to reduce the risk of 115 
acquiring human immunodeficiency virus (HIV). Corneli et al. (2014) report that, after PrEP 116 
had been found to be effective in three separate RCTs in high-risk populations, two placebo-117 
controlled RCTs conducted with women at higher risk of acquiring HIV failed to show 118 
effectiveness and were therefore closed early. [19] 119 
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 120 
However, when the data were re-analysed using a composite adherence score, based on 121 
plasma and intracellular drug concentrations, it was apparent that only 12% of participants 122 
had achieved good adherence throughout their study participation [19]. This finding raises 123 
the possibility that participants in the trial were not taking enough of the prescribed dose to 124 
see a therapeutic effect.  125 
 126 
The authors used drug concentration as a measure of adherence, instead of pill count or 127 
self-reporting, because they had previously observed that adherence was strongly 128 
overestimated with these measures.  Good adherence was defined as plasma and 129 
intracellular concentrations that could be expected if a participant had taken the study drug 130 
four or more times each week over the preceding 28 days.  131 
 132 
Medication non-adherence in clinical trials also results in increased variability and decreased 133 
effect size. The consequences vary, depending on the study design. In placebo-controlled 134 
trials, non-adherence results in decreased power, increasing the risk of type II error (the 135 
failure to show that an effective drug is effective). In positive controlled trials, there is an 136 
increased risk of type I error (erroneously claiming that drugs are equivalent). 137 
 138 
Reduced power is often mitigated by increasing the sample size, which comes at a cost to the 139 
sponsor, or by increasing the dose, which can increase unexpected adverse reactions. Partial 140 
adherence may also cause adverse events due to rebound effects.  141 
 142 
Trials that fail to show effectiveness because of non-adherence may be a widespread issue, 143 
and this suggestion is supported by the published evidence [20-23]  However, because 144 
adherence has not been measured and reported appropriately in trial settings, and because 145 
there is a tendency towards under-publication of failed trials, the data are obscured and we 146 
cannot truly know how many compounds have been affected by this problem throughout the 147 
history of drug development. 148 
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 149 
Non-adherence may also confound dose-response estimations and skew results towards 150 
overestimation of dosing requirements, which increases the risk of post-approval dose 151 
reductions [3]. Indeed, it has been estimated that 20-33% of all drugs approved since 1980 152 
have been dose-adjusted after market authorisation had been granted, and that 60-80% of 153 
the adjustments were dose reductions [24, 25].   154 
 155 
When a compound fails to reach regulatory approval as a result of non-adherence in clinical 156 
trials, the cost is likely to run into hundreds of millions of dollars annually in the US, and this 157 
cost is primarily carried by the pharmaceutical sponsor. An analysis by the Tufts Center for 158 
the Study of Drug Development suggested that the average cost of getting a drug approved 159 
is $2.6 billion [26]. Wasted costs are incurred when additional participants are enrolled to 160 
account for non-adherence. There may be opportunity costs, due to missed therapeutic 161 
effect.  There will also be a knock-on effect on patients and health care systems, because 162 
otherwise effective treatments are lost. To the best of our knowledge, the downstream 163 
financial impact of post approval dose reductions, and suspended and revoked licences, has 164 
not yet been estimated. However, these costs are likely to add up to substantial losses for the 165 
licence holders [27]. 166 
[Heading 1] Identifying appropriate adherence measures  167 
As outlined above, comprehensive evidence supports the argument that adherence to 168 
investigational drugs should always be appropriately measured, analysed and reported in all 169 
clinical trials. This section provides guidance to researchers on how to achieve this in 170 
alignment with EMERGE guideline [5]. It will discuss different approaches to measuring 171 
adherence, and explain how EMERGE could be applied in each case. 172 
There are advantages and disadvantages with all measures of adherence, and identifying the 173 
measurement most appropriate to any specific trial requires thorough consideration of the 174 
overall objectives, study design and patient population, and the points where adherence may 175 
have an impact on the trial objectives.  176 
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 177 
[Heading 2] The ABC taxonomy 178 
The first step is to identify the specific aspect(s) of adherence that must be captured. The ABC 179 
taxonomy, which is fundamental in EMERGE, defines adherence as a three-phased process by 180 
which patients take their medications as prescribed [5, 28]. Each phase is unique and must be 181 
specifically defined, measured and analysed:  182 
• A) Initiation is when the patient takes the first dose of a prescribed drug; the process 183 
then continues with  184 
• B) implementation, which is defined as the extent to which a patient’s actual dosing 185 
corresponds to the prescribed dosing regimen, from initiation until the last dose is 186 
taken; and 187 
• C) discontinuation marks the end of therapy, with the period between initiation to 188 
discontinuation referred to as persistence. 189 
Non-adherence can thus arise in a number of situations, including late- or non-initiation of 190 
prescribed treatment, sub-optimal implementation of the dosing regimen, and non-191 
persistence/early discontinuation that is not specified by the trial protocol or prescription (see 192 
Figure 1, adapted to clinical trials based on Vrijens et al 2012 [28]). 193 
 194 
The appropriate operational definition(s) of adherence, and how this can be captured, must 195 
be decided. Researchers also need to consider whether it is important to understand any 196 
reasons for non-adherence within their trial populations, which can only be captured by using 197 
patient-reported outcome measures (PROs).  198 
[INSERT FIGUE 1] 199 
 200 
[Heading 2] Specific measurements of adherence 201 
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The second step is to identify and review potential methods of measurement, taking into 202 
consideration validity, reliability and potential bias of each measure, as well as burden on 203 
participants and investigators. Table 1 presents a summary of each measurement approach 204 
noting key considerations. Further description is provided in the specific sections below. 205 
 206 
Directly observed therapy  (DOT). This is one of the only real-time measures of adherence 207 
that can guarantee drug ingestion or administration. DOT is resource intensive and primarily 208 
viable where participants are staying in a clinical setting during the trial period. DOT is 209 
therefore often used in Phase I trials with healthy volunteers, but rarely used in Phase II-Phase 210 
IV trials with ambulatory patients. McCann et al. (2015) summarised ‘DOT-proxy’ methods, 211 
including using camera/video enabled mobile phone technology where participants record 212 
ingestion and transmit the images to investigators for observation [29] (e.g. AiCure 213 
Technologies, Inc.), which may be somewhat burdensome for both parties. DOT methods 214 
could be used to assess all three phases of non-adherence in the clinical trial setting, as 215 
defined by EMERGE. However, the high burden on participants, and the intrusiveness into 216 
their lives, precludes widespread use. 217 
 218 
Pill count. Counting returned tablets is the standard practice for drug accountability in clinical 219 
trials: it is also the most commonly used method to measure adherence. However, it is easily 220 
censored by participants and only provides an aggregate summary of adherence between visit 221 
periods. It does not allow precise estimates of initiation, implementation or persistence [30, 222 
31]. 223 
 224 
Patient reported outcome measures. Self-reported adherence data is also common and is  225 
typically based on a patient-reported outcome (PRO) scale or categorical measure, or as a 226 
patient diary. There are many self-report measures and different methods of administration, 227 
with large variation in validity and reliability, burden to participants and investigators  [32,33] 228 
and large variation in licensing fees. PROs are sensitive to recall and social desirability biases 229 
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and, like pill-count, have often been found to overestimate adherence [17]. Classic 230 
administration traditionally uses pen and paper, which may have increased such biases, but 231 
there has been a move in recent years towards electronic data capture in clinical trials.  232 
 233 
A great advantage of self-report, which is often overlooked in the literature on adherence 234 
measurements, is that it is the only way to explore why a participant has acted in a certain 235 
way regarding treatment and/or trial protocol adherence [30,32]. This approach can be 236 
helpful in determining reasons for non-adherence during initiation of therapy, 237 
implementation, and ongoing persistence, providing valuable and timely insight to the drug 238 
development and study design team. Structured or semi-structured PROs can be designed to 239 
capture participants’ reasons for non-adherence [32]. However, measures that use double-240 
barrelled items to capture both the act and cause of non-adherence in one item are not 241 
recommended, as the data would be difficult to interpret.  242 
 243 
Exit interviews are increasingly used to assess adherence, and the reasons for non-adherence, 244 
in a clinical trial setting. A study by Nunn et al. (2016) provides a useful example. In people 245 
diagnosed with HIV, who were stabilised on anti-retroviral treatment, this trial assessed the 246 
risks and benefits of stopping cotrimoxazole (a prophylaxis against opportunistic infections) 247 
[34]. Exit interviews were used to assess participants’ adherence to the study procedures. It 248 
emerged that some participants were non-adherent to the trial protocol because they 249 
obtained and used open-label cotrimoxazole, although not to the extent that the trial results 250 
were seriously compromised [34]. 251 
 252 
Drug or drug metabolite monitoring. Monitoring drug or drug metabolites in plasma, urine 253 
or hair can provide a snapshot of adherence. However, such monitoring is sensitive to bias 254 
when participants ingest the investigational drug before a trial visit, even if they may have 255 
been non-adherent in the period running up to the visit (white-coat adherence) [35]. 256 
Monitoring the investigational drug in biologic fluids is also restricted to active arms of the 257 
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trial, unless an ultralow dose of the drug, which is detectable but below the lower end of the 258 
therapeutic range, is used in the control arm [29]. An alternative is to use other 259 
pharmacologically inactive biologic markers that are ingested simultaneously with the 260 
investigational or placebo compounds. The ideal marker should have an appropriate 261 
pharmacokinetic profile in terms of dosing schedule, low variability within and between 262 
participants, few drug-drug or food interactions, and should be excreted in urine or saliva. It 263 
is also essential that the marker is generally considered safe or licensed for use by regulators, 264 
and uncommon in dietary sources, supplements and pharmaceuticals [36]. Another potential 265 
drawback is that the biological marker would need to be added to the formulation of the 266 
investigational drug. [3] This method could be used as a measure of adherence 267 
implementation, given the drawbacks mentioned above are addressed, but it cannot be used 268 
to determine initiation or persistence, unless daily sampling is undertaken.   269 
 270 
Electronic detection of package entry. Electronic monitoring incorporated in medication 271 
packaging, pioneered by the Medication Event Monitoring System (MEMS®, AARDEX Group, 272 
see [37]), allows for date and time stamped recordings when the participant opens the 273 
pharmaceutical package. MEMS was originally designed as an electronic cap to capture the 274 
opening and closing of a standard pharmaceutical bottle. The principle can easily be extended 275 
to other drug delivery systems, including blister packaging, injections and inhalers. To date, 276 
more than 810 papers in peer-reviewed journals report diverse uses of MEMS in research 277 
settings and a multitude of companies offer smart packaging. 278 
 279 
It is assumed that a correct dose of the investigational drug is ingested each time the 280 
packaging is opened, and that the continuous data captured will clearly display adherence 281 
patterns over time. These recording devices require minimal management from participants 282 
and investigators. Electronic detection of package entry is an indirect measure of dose intake 283 
and there could be instances where the package is activated but a dose is not taken. [31] 284 
Studies comparing MEMS data with drug concentrations show that there is 97% accuracy 285 
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between opening the pharmaceutical package and time of ingestion of the prescribed dose 286 
[3].  287 
In drug trials, this method can be used to precisely identify the time of initiation and the time 288 
of eventual treatment discontinuation. Furthermore, it allows reliable and sound compilation 289 
of each patient’s implementation of the dosing regimen.  290 
 291 
Ingestible sensors (breath inhaler, smart pill) and electronic detection of ingestion. 292 
Technological approaches to measuring adherence are emerging at a rapid rate. These 293 
include breathalysers (i.e. SMART®; Xhale, Inc.), monitors for inhalers (i.e. the Inhaler 294 
Compliance Assessment; INCA™), and ingestible sensors (i.e.  Proteus Digital Health, Inc. and 295 
eTectRx, Inc.).  Each can be used to assess adherence across the initiation, implementation 296 
and persistence stages of the clinical trial data collection process that are described in 297 
EMERGE. Many can confirm that the drug has been ingested by the participant, although 298 
some sensors have technical limitations and, alternatively, allow users to record an event by 299 
pressing a button [38]. These measures may also provide insights into patterns of adherence 300 
and non-adherence, although they may not be feasible when investigating  specific drugs or 301 
in all contexts of use. For example, ingestible sensors can only be used with solid oral 302 
medication and require drug reformulation. In addition, where a skin patch is required to 303 
detect the signal, the user must maintain the patches over the treatment period: skin 304 
irritation and inflammation are commonly reported [38]. Ingestible sensors may also be 305 
perceived as intrusive by users [39].   306 
 307 
Claims and refills. Measures such as pharmacy refill and insurance claims data, which are 308 
used in adherence research, are not appropriate in a Phase I-III clinical trial setting where 309 
participants tend to be given the investigational drug during trial visits and the cost of the 310 
treatment is funded by the sponsor. This approach may only be relevant for studies in the 311 
post-approval stage, that is, Phase IV registry studies. In addition, such data do not provide 312 
information on any errors related to dose and timing of administration, which is crucial in 313 
terms of understanding exposure-response [3]. 314 
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 315 
Multiple complementary measures. A trial design that aligns with EMERGE by considering  316 
appropriate definitions of the aspect(s) of adherence to be captured (initiation, 317 
implementation and persistence), may prompt the need for multiple complementary 318 
adherence measures. The use of complementary measures is distinct from measurement 319 
triangulation, in that each measure should measure a distinct element of adherence, and each 320 
should be defined and reported according to EMERGE [5]. 321 
 322 
[INSERT TABLE 1] 323 
[Heading 1] Adherence interventions in trial settings  324 
Regulators have taken notice of the potential benefit of supporting adherence in trial settings. 325 
The FDA’s guidance for Enrichment Strategies for Clinical Trials to Support Approval of Human 326 
Drugs and Biological Products (2019) acknowledges that good adherence in a trial can 327 
increase the power of a study –its ability to demonstrate a treatment effect if one is present 328 
– by decreasing variability that is unrelated to the study drug [6]. One strategy is to identify 329 
and select patients who are likely to adhere to treatment, but only prior to randomisation, 330 
not afterwards. Otherwise, this step could impact the statistical validity and conclusions of 331 
the trial: indeed, adherence alone, even to placebo,  has been linked to better outcomes in a 332 
trial. In addition, a protocol that is partially masked to participants and investigators during a 333 
run-in period can reduce the risk that adherence may be overly and artificially encouraged.  334 
Other measures discussed include making patients aware of the conditions and demands of 335 
the trial, avoiding overly rapid initial titrations to reduce initial side effects, and using 336 
adherence prompts and feedback, for example, using dosing history data from smart bottles 337 
to encourage good adherence. These strategies can also be used in safety assessments [6].  338 
It is also advisable to consider complexity and stringency when designing a trial protocol to 339 
facilitate adherence [36]. 340 
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SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) is an 341 
international initiative that aims to improve the quality of clinical trial protocols, by defining 342 
an evidence-based set of items that should be included in a clinical trial protocol [40, 41].  One 343 
component of this is a section on adherence, which provides guidance on procedures and 344 
strategies for monitoring and improving adherence and reporting this clearly in the study 345 
protocol.  346 
Adherence interventions in a trial setting mainly fall into two categories: 1) approaches to 347 
identify adherence issues in the trial preparation and run-in phases; and 2) approaches to 348 
directly improve adherence to the trial protocol and/or the investigational drug.  349 
 350 
[Heading 2]  Trial preparation and run-in phases  351 
Previous participation in another trial, within a specific time period, is a common criterion for 352 
participant exclusion. However, some participants have been shown to mislead investigators 353 
about this point [29]. One solution is to use participant registries, and this precaution may 354 
reduce the risk of enrolling participants who are involved in multiple trials [36]. In some 355 
markets, including France and the United Kingdom, registration of Phase I volunteers is 356 
mandatory. It is increasingly apparent that this requirement is needed for Phase II – IV trials.  357 
 358 
Some pharmaceutical sponsors use participant identifiers to identify duplicate enrollers in 359 
their own trials. However, these techniques do not identify them across sponsors. There are 360 
also various systems, including Verified Clinical Trials, CTSdatabase and Dupcheck, which use 361 
GDPR and HIPPA compliant databases to identify duplicate enrollers and thus verify eligibility 362 
[36]. 363 
 364 
Shiovitz et al. (2016) recommend sharing only limited inclusion and exclusion criteria during 365 
recruitment, to ensure participants do not have the information they would need to feign 366 
inclusion characteristics. Other recommendations include ensuring stipends are reasonable, 367 
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to discourage “professional” subjects and reduce the risk of coercing participation, and 368 
requiring site investigators to enrol at least half of participants from internal databases that 369 
offer a known source of eligible participants. The authors further recommend that 370 
investigators should be reimbursed appropriately in terms of screen-fail ratios, as a low 371 
screen-fail ratio may encourage investigators to screen in ineligible participants in order to 372 
secure payment [36]. 373 
 374 
As discussed above, the use of single-blind placebo run-in periods with adherence monitoring 375 
has been recommended, to identify participants who are inclined to respond to placebo, and 376 
those inclined to be non-adherent to the investigational drug and/or protocol requirements 377 
[6, 29]. These participants can thus be excluded according to predefined criteria or accounted 378 
for in the analysis of the trial. As noted in the FDA guidance, it is important that identification 379 
is done before randomisation [6].  380 
 381 
The FDA guidance describes the run-in period approach as an enrichment strategy that has 382 
the potential to decrease heterogeneity (non-drug related variability) and thus increase study 383 
power to detect a real drug effect [6]. However, investigators must carefully consider exactly 384 
how to analyse data from participants who, during the run-in period, have been identified as 385 
placebo responders or low adherers. This decision must be guided by the objective of the 386 
study [3]. It may not always be appropriate to simply exclude these participants. Instead, the 387 
information may be used to inform the analysis of sub-populations.  388 
 389 
Despite recommending them, the FDA guidance recognises that enrichment strategies may 390 
limit the generalisability and applicability of the study results. [6] Therefore, care should be 391 
taken to ensure that sufficient data are collected on the full range of individuals who may 392 
later receive the drug post-approval.  393 
 394 
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[Heading 2] Approaches to directly improve adherence 395 
The FDA guidance also describes a range of methods that can be used to positively affect 396 
adherence [6]. However, the ethics of directly encouraging ingestion of an investigational 397 
drug need to be carefully considered, in particular before efficacy and safety have been 398 
established, as a trial participant must remain free to discontinue treatment without 399 
explanation and prejudice, and must also feel free to report any adverse reactions or 400 
experiences of taking the drug [29]. FDA guidance recommends adherence feedback at the 401 
point of care to avoid this ethical issue. To avoid potential source of bias, it is recommended  402 
to provide standard adherence monitoring and support to all participants in both active and 403 
placebo arms. 404 
 405 
McCann et al. (2016) recommend financial incentives, not to increase adherence but rather, 406 
to encourage participants to report adherence accurately, whether the drug has been taken 407 
or not [29]. However, this approach carries the risk of biasing a participant’s response, 408 
because they are incentivised to give a response at each point of measurement. 409 
 410 
One strategy that has great potential is patient-centred trial design. It can encourage 411 
adherence not only to the requirements of the study period but also throughout follow-up, 412 
which is often lengthy. This approach includes steps such as: seeking patient input at the 413 
design stage, to ensure patient-friendly study materials and processes are used to help 414 
explain and implement the clinical trial; choosing outcomes that are meaningful to patients; 415 
and minimising participant burden from clinic visits via greater use of at-home electronic data 416 
capture. [42]  417 
 418 
[Heading 1] Analysing and interpreting adherence data in clinical trials 419 
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This section links to items 5 – 8 in the EMERGE guideline, which describe the trial design and 420 
statistical analysis elements that should be considered a priori and reported at the end of the 421 
trial [5].  422 
 423 
Non-adherence to a planned treatment regimen in placebo-controlled trials can diminish the 424 
causal treatment effect (i.e. efficacy) and make a treatment look less effective than it really is 425 
[36, 43, 44]. This causes many problems, some of which have been discussed above.  426 
 427 
In placebo-controlled trial analysis, non-adherence fundamentally alters what is meant by the 428 
‘treatment effect’. If non-adherence is ignored in the statistical analysis, the true efficacy of 429 
treatment will be diminished, resulting in overly conservative estimates of efficacy. In 430 
contrast, in safety analyses and in analyses of non-inferiority and equivalence trials, the 431 
diminishing effect of non-adherence is usually anti-conservative, which means a harmful 432 
treatment is more likely to be accepted as harmless and equivalency or non-inferiority are 433 
more likely to be declared [44,45]. There is also some evidence that patterns and causes of 434 
non-adherence can influence the treatment effect in different ways, making it difficult to 435 
predict the overall effect [46,47]. 436 
 437 
A recent review found that a majority of trials are subject to various forms of non-adherence 438 
to the treatment protocol, and investigators attempt to deal with non-adherence using a 439 
variety of statistical methods and analysis populations. However, they rarely consider the 440 
potential for the introduction of bias [45]. Here, we present recent research and 441 
recommendations on how to account for non-adherence in trial analyses, to better estimate 442 
treatment efficacy.  443 
 444 
[Heading 2] Planned approaches 445 
If non-adherence is foreseeable in a trial, investigators should plan for this at the design 446 
stage, both to demonstrate transparency and to ensure all data that will be necessary for 447 
analysis are collected. Dodd et al. (2017) have published a useful set of recommendations to 448 
enable adequate data collection [43]. For analysis, current draft International Conference on 449 
Harmonisation (ICH) guidelines (E9(R1) 2017) state that clear trial objectives should be 450 
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translated into key scientific questions of interest, and suitable estimands  (the target of 451 
estimation for these questions, see box) chosen to address them, before an appropriate 452 
statistical analysis plan is specified. EMERGE sections 7 and 8 can guide the selection of an 453 
estimand by helping to define the parameters of non-adherence [5] After the estimands are 454 
settled, an appropriate statistical analysis can be specified [7].  455 
 456 
[Heading 3] Intention-to-treat 457 
It is generally recommended to perform the primary efficacy analysis under the intention-to-458 
treat (ITT) principle [43], where all participants are included in the analysis and treatments 459 
are compared between randomised arms, regardless of which treatment the participants 460 
actually received. This preserves the element of randomisation, ensuring that no baseline 461 
confounding is expected to affect the analysis. Current ICH guidelines describe five ITT 462 
strategies, each for different estimands of subtly different treatment effects of interest [7]. 463 
The first is treatment policy, which is the strategy most commonly associated with ITT 464 
analyses and the one prone to underestimating efficacy. This estimand is useful in pragmatic 465 
trials that are looking for the population effect of implementing a treatment policy, with real-466 
world deviations from the protocol taken into account. 467 
 468 
[Heading 3] Additional strategies 469 
However, when interest lies in more precisely estimating efficacy, and appropriate data on 470 
adherence are available, the remaining four strategies can be employed in addition to (or 471 
instead of, depending on the aims of the trial) the treatment policy strategy. Briefly, these 472 
are:  473 
1. The composite strategy, where non-adherence is integrated into the (adverse) 474 
outcome of interest.  With this strategy we assume non-adherence adds meaningful 475 
information about the overall effect of the treatment.  As an example, perhaps 476 
participants did not adhere to the treatment because they could not tolerate it,  or 477 
they experienced other adverse events that had an influence on the treatment effect. 478 
The outcome would be expanded to include either the event under study, or failure 479 
to adhere to or withdrawal from treatment, and randomised groups would be 480 
compared in an appropriate statistical analysis.  481 
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2. The hypothetical strategy, where the treatment effect is that which would have been 482 
seen if everyone had adhered perfectly to treatment through the end of follow-up. 483 
Strong assumptions are required for this effect to be meaningful, including that 484 
medication non-adherence was unrelated to tolerability (see ICH E9 (R1) guidelines 485 
for further discussion).  In this strategy, outcome measurements that were not 486 
observed due to non-adherence can be imputed under plausible missingness 487 
assumptions, and an appropriate statistical analysis can be performed on the imputed 488 
dataset(s). 489 
3. The principle stratum strategy, where the treatment effect is that which would be 490 
seen in the stratum of people who 1) would be able to perfectly adhere to either 491 
treatment, and 2) would actually do so. This subset of randomised participants cannot 492 
be directly known because valid reasons for non-adherence (such as medication 493 
intolerability) cannot be predicted in advance, and they cannot be inferred after the 494 
trial has been completed as participants can only receive one treatment. However, 495 
investigators can attempt to infer membership in this stratum from covariates and 496 
perform the statistical analysis on data from these participants only. At the design 497 
stage investigators may also consider specifying markers of good adherence and 498 
restricting participation with relevant inclusion or exclusion criteria and/or they may 499 
consider using special trial designs such as run-in, enrichment or randomised 500 
withdrawal, though these strategies may decrease the generalisability of the results.  501 
4. The while on treatment strategy, where the treatment effect is a weighted average 502 
of the outcomes seen while adhering to treatment (rather than the effect seen by a 503 
pre-specified time point). An appropriate statistical analysis that accounts for time in 504 
adherence can then be performed. 505 
Which one to use will depend on the estimand of interest. Since all of these strategies are 506 
underpinned by assumptions, it is best to use one or more sensitivity analyses to test them. 507 
For a thorough discussion, see the ICH Harmonised Guideline for Estimands and Sensitivity 508 
Analyses in Clinical Trials [7].  509 
 510 
[Heading 2] Less preferable strategies  511 
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Other analysis principles,  such as per-protocol (PP) and as-treated (AT) analyses, attempt to 512 
address questions of adherence and efficacy. However, they are not usually suitable. PP 513 
analyses typically exclude or censor participants who deviate from the treatment protocol, 514 
before comparing treatments between randomised arms. However, because the treatment 515 
protocols are likely to present different challenges to adherence, the participant groups may 516 
not be comparable [44]. AT analyses include all participants, but analyse them according to 517 
the treatment they actually received, discarding randomisation. Both of these analyses are 518 
prone to selection bias, so confounding must be considered and appropriately adjusted for in 519 
statistical analysis. As it is usually not possible to completely adjust for all possible sources of 520 
confounding, neither of these is preferable to an appropriately designed ITT analysis. 521 
 522 
[Heading 2] Unplanned approaches 523 
If non-adherence was not considered during trial design (so no planned analyses incorporate 524 
it), but relevant data are available for analysis, investigators may decide to perform one of 525 
the above analyses post-hoc. However, care must still be taken in selecting an appropriate 526 
estimand and, as with all post-hoc investigations, investigators must use caution and avoid 527 
over-interpreting results from unplanned analyses.  528 
 529 
More advanced statistical techniques can also estimate causal treatment effects and account 530 
for non-adherence to treatment, while maintaining the balance produced by randomisation. 531 
Some examples include randomisation-based efficacy estimation [48] instrumental variable 532 
[49], and complier average causal effect (CACE) [50] methods. Such analysis techniques are 533 
not yet commonly used, as they tend to be more complex and/or computationally intensive 534 
than the previously discussed analyses. They also rely on potentially unverifiable 535 
assumptions, which are often stronger than those required for ITT analyses. However, this 536 
area of research is growing and some [35] are calling for increased awareness and uptake of 537 
these methods. 538 
 539 
Although it may be possible to estimate causal treatment effects after a trial has started, or 540 
even after it has ended, pre-planned statistical analyses always give weightier and more 541 
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transparent results than post-hoc analyses. Therefore, identifying potential adherence issues 542 
early in the clinical trial programme is crucial. 543 
 544 
[Heading 2] Safety analyses 545 
Although much research has gone into methods of accounting for non-adherence in 546 
estimating treatment efficacy, there is to our knowledge no research and guidance on the 547 
appropriate analysis population to use for harms outcomes in the presence of such 548 
nonadherence [45]. This is likely due to a more widespread lack of good practice around 549 
collecting, reporting and analysing harms in clinical trials. A recent systematic review [51] of 550 
trial results reported in four high-impact journals found that these items were inconsistently 551 
undertaken and concluded that statistical analysis, in particular, was often deemed 552 
inappropriate and suboptimal, potentially leading to missed harm signals and unsafe 553 
treatments being declared safe. In addition, because adverse events are unpredictable in 554 
advance, safety analyses are not often well-powered. The problem of low power is 555 
exacerbated by non-adherence, which could preclude the observation of adverse events that 556 
would otherwise have occurred; further, non-adherence could itself be a consequence of side 557 
effects that were on the path towards an adverse event. More research is needed on how to 558 
deal with non-adherence in safety analyses. 559 
 560 
[Heading 1] Reporting adherence data from clinical trials 561 
The EMERGE guidelines [5] should be used in harmony with reporting guidelines for clinical 562 
trials, such as STROBE [9] and CONSORT, [8] to ensure that all the relevant aspects of the 563 
adherence data are reported in a relevant and appropriate manner. The minimum reporting 564 
criteria include: 1) the phases of adherence being studied; 2) the operational definition of 565 
each adherence phase; 3) the measurement method/s used; and 4) the results of the analysis 566 
appropriate for each phase being studies [5]. 567 
 568 
[SUGGESTED CALL OUT BOX TEXT] 569 
An estimand is simply a treatment effect ‘of interest’ for a clinical question. The treatment 570 
effect in a perfect setting, where 100% of trial participants would adhere to their treatment 571 
throughout the entire follow-up period, is a pure effect of the treatment. It is how the 572 
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outcome of treatment, taken exactly as prescribed, compares to what would have happened 573 
to the same subjects had they all taken the alternative (or no) treatment exactly as prescribed. 574 
Often this is the effect ‘of interest’; however, non-adherence reduces or increases the amount 575 
of exposure to the treatment and muddles this interpretation. In this situation there are 576 
several possible ‘treatment effects’ that could be obtained, each answering slightly different 577 
questions.  578 
 579 
The EMERGE guideline highlights the information required to define an estimand for a clinical 580 
trial that factors adherence into the treatment effect. Estimands have four elements [7]: 581 
1. the target population (e.g. the stratum of participants who would adhere to treatment 582 
if they could tolerate it: EMERGE items 5a-5c elicit information to help define this [5]) 583 
2. the variable or endpoint to be obtained for each participant (e.g. treatment failure 584 
defined as non-response or treatment discontinuation: EMERGE item 6a [5]) 585 
3. the specification of how to account for non-adherence and other treatment-altering 586 
events (see text for a description of potential strategies: EMERGE items 7a-b[5])  587 
4. the population-level summary for the variable, which can be compared between 588 
treatment conditions (e.g. mean change in outcome or proportion of treatment 589 
failures: EMERGE items 8a-b, 9a-b [5]). 590 
 591 
 [END OF BOX TEXT] 592 
 593 
[Heading 1] Conclusions 594 
Unidentified non-adherence in clinical trial settings is a substantial and costly challenge that 595 
directly or indirectly affects all stakeholders. Non-adherence in clinical trials can obscure 596 
exposure-response estimations  and confound safety and efficacy signals. Addressing this 597 
issue offers benefits to all. For drug developers, it is likely to be more cost-effective to identify 598 
and manage non-informative data or use trial enrichment strategies to increase study power, 599 
than to manage the effect of non-adherence by increasing sample size [36].  Patients stand to 600 
benefit from safer and more effective dosing regimens, which have been established based 601 
on adherence-informed results [3].  The EMERGE guideline [5] can help drug developers and 602 
researchers to better understand how adherence data should be collected, analysed, and 603 
reported in clinical trial settings, and can be used to drive improvement in addressing the 604 
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pervasive issue of non-adherence in clinical trials. To align with previously published guidance 605 
specifying that adherence to investigational products and trial protocols should be adequately 606 
reported [6,7], pharmaceutical regulators need to officially endorse EMERGE [5] to drive 607 
positive change, and ensure clinical trial sponsors and research organisations can achieve 608 
appropriate alignment with these guidelines. 609 
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Table 1. Potential adherence measures to assess initiation, implementation, and/or 777 
persistence, as well as reasons for non-adherence 778 
Adherence 
measure 
Initiation date Implementation Discontinuation 
date 
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Figure legends 782 
Figure 1. Illustration of the process of medication adherence according to the ABC Taxonomy 783 
[28] adapted to a clinical trial setting. The example is illustrating a twice a day dosing 784 
schedule. 785 
